专题：Platelet Disorders and Treatments

This cluster of papers focuses on platelet disorders, thrombosis mechanisms, and related conditions such as immune thrombocytopenic purpura and von Willebrand disease. It covers topics including platelet function, hemostasis, inflammation, megakaryocyte development, and the molecular mechanisms underlying thrombus formation.
最新文献
Comparison of clinical characteristics in primary immunodeficiency patients based on the presence of autoimmunity or autoinflammation

article Full Text OpenAlex

Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia

article Full Text OpenAlex

Propofol and/or etomidate-induced immune thrombocytopenia: A case report

article Full Text OpenAlex

Platelets as immune sensors: monitoring immune dynamics and diagnosing disease states across multiple disorders

article Full Text OpenAlex

Von Willebrand Factor at the Crossroads of Hemostasis and Inflammation

article Full Text OpenAlex

The Role of Platelets Beyond Hemostasis

article Full Text OpenAlex

Structural Analysis of von Willebrand Factor

article Full Text OpenAlex

Immune Response Mechanisms in Haemophilia A

article Full Text OpenAlex

Hematopoiesis could be improved by correcting aberrant bone marrow macrophages polarization in aplastic anemia patients

article Full Text OpenAlex

ER-associated degradation pathway protein SEL1L plays an evolutionarily conserved role in platelet adhesion

article Full Text OpenAlex

近5年高被引文献
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update

article Full Text OpenAlex 423 FWCI65.3438

2023 ACR/EULAR antiphospholipid syndrome classification criteria

article Full Text OpenAlex 370 FWCI93.6445

Long-Term Outcomes in IgA Nephropathy

article Full Text OpenAlex 331 FWCI67.2177

The role of platelets in immune-mediated inflammatory diseases

review Full Text OpenAlex 285 FWCI85.77

Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial

article Full Text OpenAlex 239 FWCI48.9115

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

article Full Text OpenAlex 231 FWCI46.6298

Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management

review Full Text OpenAlex 231 FWCI58.7823

Tetraspanins distinguish separate extracellular vesicle subpopulations in human serum and plasma – Contributions of platelet extracellular vesicles in plasma samples

article Full Text OpenAlex 227 FWCI18.4944

Mechanisms of Resistance to Noncovalent Bruton’s Tyrosine Kinase Inhibitors

article Full Text OpenAlex 223 FWCI32.2759

The therapeutic age of the neonatal Fc receptor

review Full Text OpenAlex 216 FWCI51.8981